Warner Bryce M, Chan Mable, Tailor Nikesh, Vendramelli Robert, Audet Jonathan, Meilleur Courtney, Truong Thang, Garnett Lauren, Willman Marnie, Soule Geoff, Tierney Kevin, Albietz Alixandra, Moffat Estella, Higgins Rick, Santry Lisa A, Leacy Alexander, Pham Phuc H, Yates Jacob G E, Pei Yanlong, Safronetz David, Strong James E, Susta Leonardo, Embury-Hyatt Carissa, Wootton Sarah K, Kobasa Darwyn
Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada.
Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.
Vaccines (Basel). 2024 Apr 10;12(4):404. doi: 10.3390/vaccines12040404.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged following an outbreak of unexplained viral illness in China in late 2019. Since then, it has spread globally causing a pandemic that has resulted in millions of deaths and has had enormous economic and social consequences. The emergence of SARS-CoV-2 saw the rapid and widespread development of a number of vaccine candidates worldwide, and this never-before-seen pace of vaccine development led to several candidates progressing immediately through clinical trials. Many countries have now approved vaccines for emergency use, with large-scale vaccination programs ongoing. Despite these successes, there remains a need for ongoing pre-clinical and clinical development of vaccine candidates against SARS-CoV-2, as well as vaccines that can elicit strong mucosal immune responses. Here, we report on the efficacy of a Newcastle disease virus-vectored vaccine candidate expressing SARS-CoV-2 spike protein (NDV-FLS) administered to cynomolgus macaques. Macaques given two doses of the vaccine via respiratory immunization developed robust immune responses and had reduced viral RNA levels in nasal swabs and in the lower airway. Our data indicate that NDV-FLS administered mucosally provides significant protection against SARS-CoV-2 infection, resulting in reduced viral burden and disease manifestation, and should be considered as a viable candidate for clinical development.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）于2019年末在中国爆发不明原因病毒性疾病后出现。从那时起，它在全球范围内传播，引发了一场大流行，导致数百万人死亡，并产生了巨大的经济和社会后果。SARS-CoV-2出现后，全球迅速广泛地研发了多种候选疫苗，这种前所未有的疫苗研发速度使得一些候选疫苗立即进入临床试验阶段。现在许多国家已批准疫苗紧急使用，大规模疫苗接种计划正在进行。尽管取得了这些成功，但仍需要对针对SARS-CoV-2的候选疫苗以及能够引发强烈黏膜免疫反应的疫苗进行持续的临床前和临床开发。在此，我们报告了一种表达SARS-CoV-2刺突蛋白的新城疫病毒载体候选疫苗（NDV-FLS）对食蟹猕猴给药后的疗效。通过呼吸道免疫接种两剂该疫苗的猕猴产生了强烈的免疫反应，鼻拭子和下呼吸道中的病毒RNA水平降低。我们的数据表明，黏膜给药的NDV-FLS对SARS-CoV-2感染提供了显著保护，导致病毒载量和疾病表现降低，应被视为临床开发的可行候选疫苗。
